NeuBase Therapeutics, Inc. / Fundamentals

    Income statement

    Net revenue
    €0.00
    Cost of goods sold
    €737.63K
    Gross profit
    -€737.03K
    SG&A expenses
    €7.87M
    R&D expenses
    €3.70M
    EBITDA
    -€11.14M
    D&A
    €1.78M
    EBIT
    -€13.17M
    Interest expenses
    €4.38K
    EBT
    -€11.85M
    Tax expenses
    -€837.46K
    Net income
    -€11.85M

    Cash flow statement

    Net deferred tax
    €48.70K
    Non-cash items
    €865.63
    Changes in working capital
    -€1.76M
    Operating cash flow
    -€12.76M
    Capex
    €54.63K
    Other investing cash flow
    €7.34
    Net investing cash flow
    -€47.29K
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €3.84M
    Debt repayment
    €0.00
    Other financing cash flow
    €3.67M
    Net financing cash flow
    €3.67M
    Foreign exchange effects
    €2.14
    Net change in cash
    -€9.13M
    Cash at end of period
    €10.85M
    Free cash flow
    -€12.70M

    Balance sheet

    Cash and cash equivalents
    €10.85M
    Cash and short-term investments
    €10.85M
    Total receivables
    €0.00
    Inventory
    €0.00
    Other current assets
    €80.22K
    Total current assets
    €11.52M
    Property, plant & equipment
    €4.44M
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €108.22K
    Total non-current assets
    €4.55M
    Total assets
    €16.07M
    Accounts payable
    €223.22K
    Short-term debt
    €432.22K
    Other current liabilities
    €2.93M
    Total current liabilities
    €4.01M
    Long-term debt
    €4.17M
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    -€0.00
    Total non-current liabilities
    €4.17M
    Total liabilities
    €8.19M
    Common stock
    €321.91
    Retained earnings
    -€100.52M
    Other equity
    €0.00
    Total equity
    €7.89M
    Total liabilities and shareholders' equity
    €16.07M

    Company information

    Market capitalization
    €1.21M
    Employees
    37
    Enterprise Value
    -€15.74M

    Company ratios

    Gross margin
    0.0%
    EBITDA margin
    0.0%
    EBIT margin
    0.0%
    EBT margin
    0.0%
    Net margin
    0.0%
    ROE
    -150.3% Much better than peer group: -10,954.2%
    ROA
    -73.7% Much better than peer group: -10,859.1%
    Asset turnover
    0.0%
    FCF margin
    0.0%
    FCF yield
    -1,059.2%
    Efficiency ratio
    0.0%
    Net sales per employee
    €0.00
    Net income per employee
    -€320.26K

    Notifications